Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pozelimab Process A vs Process B in Healthy Adults
NCT04491838Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pozelimab in CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and 1 more (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration up to 16 weeks and Peak Plasma Concentration up to 16 weeks. Started Aug 2020; status: completed.
02
Drugs
pozelimab
03
Conditions
CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathyparoxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04491838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491838.